Rani Therapeutics Holdings Inc Class A

Research Rani Therapeutics Holdings Inc Class A (RANI) on Bullrun: market cap USD 100.24M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 100.24M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 1.63M-USD 29.67M-USD 18.80Mn/a-0.45USD 18.62MUSD 0USD 33.01M
FY2024USD 1.03M-USD 30.02M-USD 35.76Mn/a-1.05USD 3.76MUSD 24.61MUSD 1.99M
FY2023USD 0-USD 33.97M-USD 52.47Mn/a-1.33USD 5.86MUSD 29.38MUSD 12.87M
FY2022USD 0-USD 30.59M-USD 48.13Mn/a-1.28USD 27.01MUSD 29.15MUSD 36.86M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 100.24Mn/an/an/a
20252025-12-31USD 131.79Mn/an/an/a
20242024-12-31USD 45.80Mn/an/an/a
20232023-12-29USD 85.92Mn/an/an/a
20222022-12-30USD 145.85Mn/an/an/a
20212021-12-31USD 322.29Mn/an/an/a

About Rani Therapeutics Holdings Inc Class A

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Rani Therapeutics Holdings Inc Class A's market cap?

Rani Therapeutics Holdings Inc Class A's market capitalization is USD 100.24M.

What does Rani Therapeutics Holdings Inc Class A do?

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.